Paper Details

  1. Home
  2. Paper Details

Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India.

Author: BalasubramanianR, JawaharM S, ParamasivanC N, RamachandranR, SelvakumarN, SivasubramanianS, SomasundaramP R, VijayanV K

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared three treatment regimens for tuberculosis in 325 patients. The most effective regimen involved daily treatment with rifampicin, streptomycin, isoniazid, and pyrazinamide for 3 months, followed by twice-weekly treatment with streptomycin, isoniazid, and pyrazinamide for 2 months (R5). This regimen had a significantly lower relapse rate (5.2%) compared to a 3-month daily regimen (R3, 16.8%) and a similar regimen without rifampicin (Z5, 20%). Relapse rates were also higher in patients with bacteria initially resistant to antibiotics. This study suggests that a longer treatment course with rifampicin is more effective in preventing tuberculosis relapse.
Paper Details　
Original Abstract of the Article :
A controlled study of three short-course regimens was undertaken in South Indian patients with newly diagnosed, sputum-positive pulmonary tuberculosis. The patients were allocated at random to one of three regimens: a) Rifampicin, streptomycin, isoniazid and pyrazinamide daily for 3 months (R3); b) ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0041-3879(90)90037-9

データ提供：米国国立医学図書館（NLM）

Short-Course Regimens for Pulmonary Tuberculosis: A Five-Year Assessment

Pulmonary tuberculosis (TB), a contagious bacterial infection that primarily affects the lungs, is like a persistent desert wind, threatening human health. This study examines the efficacy of three short-course regimens for treating sputum-positive pulmonary TB, seeking to find the most effective and efficient treatment strategy. This research is like a camel caravan traversing a challenging desert, searching for the most efficient and effective route to overcome the challenges of TB. The researchers meticulously followed patients for five years, assessing the effectiveness of the different regimens in preventing bacteriological relapse. This rigorous approach is like carefully observing the desert landscape, ensuring accuracy and long-term sustainability of the findings.

Short-Course Regimens: A Promising Approach

The study revealed that the 5-month regimen (R5), which included rifampicin, streptomycin, isoniazid, and pyrazinamide, followed by continued treatment with streptomycin, isoniazid, and pyrazinamide, was significantly more effective than the 3-month regimen (R3) in preventing bacteriological relapse. This discovery is like finding a hidden oasis in the desert of TB, offering a more effective and efficient treatment strategy. This suggests that extending the treatment duration for certain patients could lead to better outcomes and reduce the risk of relapse.

Optimizing TB Treatment

This study provides valuable insights into the effectiveness of short-course regimens for treating pulmonary TB. It highlights the importance of carefully considering treatment duration and regimen selection based on individual patient needs. This knowledge is like a compass guiding healthcare professionals through the complexities of TB treatment, enabling them to optimize patient care.

Dr.Camel's Conclusion

This five-year study provides valuable insights into the effectiveness of short-course regimens for treating pulmonary tuberculosis. It highlights the importance of carefully considering treatment duration and regimen selection to optimize patient outcomes and reduce the risk of relapse.

Date :
  1. Date Completed 1991-02-11
  2. Date Revised 2019-09-07
Further Info :

Pubmed ID

2125153

DOI: Digital Object Identifier

10.1016/0041-3879(90)90037-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.